Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist

Urologia Internationalis

Volumn 66, Issue 3, 2001, Pages 135-139

  Tsushima, Tomoyasu ^a   Nasu, Yasutomo ^a   Saika, Takashi ^a   Maki, Yoshio ^b   Noda, Masatoshi ^c   Suyama, Bunzo ^d   Yamato, Toyoko ^e   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Konko Hospital   (Japan)

^c KOBE UNIVERSITY   (Japan)

^d Mitoyo General Hospital   (Japan)

^e Okayama Citizens Hospital   (Japan)

Author keywords

Flare up; Flutamide; Gonadotropin releasing hormone agonist; Prostate cancer

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FLUTAMIDE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0035027393     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056592     Document Type: Article

References (14)

1. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders
2. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
3. DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate
4. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
5. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation
6. Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: Combination therapy with diethylstilbestrol
7. Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy
8. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteiniz-ing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate
9. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate
10. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol
11. Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate
12. Prevention of the initial testosterone surge induced by a lu-teinizing hormone-releasing hormone analogue in prostate cancer patients: The endocrinological effects of pretreatment with chlormadinone acetate
13. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)
14. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist